Predicting Age-Related Facial Hyperpigmentation via Dermatologist Knowledge Elicitation and Generative Modeling [0.03%]
基于皮肤科医生的知识提取和生成模型的年龄相关性面部色素沉着预测
Edouard Raynaud,Laudine Bertrand,Frederic Flament et al.
Edouard Raynaud et al.
Introduction: Facial hyperpigmentation is a primary marker of skin aging in Asian populations. While many artificial intelligence (AI)-based aging simulators exist on social media, they often lack scientific transparency ...
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) [0.03%]
莱比库珠单抗治疗中重度特应性皮炎 3 年疗效和安全性：长期扩展研究（ADjoin）
Emma Guttman-Yassky,Alan D Irvine,Melinda Gooderham et al.
Emma Guttman-Yassky et al.
Introduction: We report efficacy and safety of lebrikizumab up to 152 weeks (W) of continuous treatment with/without topical corticosteroids in the ADjoin long-term extension study. ...
Beyond Drainage: Clinical-Ultrasound Correlation Supports a Broader Definition of the Active Tunnel in Hidradenitis Suppurativa [0.03%]
超越引流：临床超声波相关性支持对汗腺炎的活跃隧道进行更广泛的定义
Antonio Martorell,Francisco Javier Melgosa Ramos,Pedro Navarro Guillamón
Antonio Martorell
Introduction: Current severity classification systems for hidradenitis suppurativa (HS) define tunnel activity almost exclusively by the presence of purulent drainage. In daily clinical practice, however, non-draining tun...
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence [0.03%]
一种用于特应性皮炎的持久性指数：雷布キ珠单抗、杜普Il玛鲁单抗和Tra洛inki珠单抗在不同治疗依从性下维持疗效的间接比较
Jonathan I Silverberg,Alan D Irvine,Peter Foley et al.
Jonathan I Silverberg et al.
Introduction: Real-world management of moderate-to-severe atopic dermatitis (AD) may involve treatment interruptions. This indirect comparison evaluated the efficacy of lebrikizumab, dupilumab, and tralokinumab monotherap...
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment [0.03%]
特应性皮炎患者的治疗属性偏好：一项离散选择实验
April W Armstrong,Aseel Bin Sawad,Nisha C Hazra et al.
April W Armstrong et al.
Introduction: The treatment landscape for Chronic Hand Eczema (CHE) is evolving; however, evidence on patients' preferences regarding CHE treatment attributes is sparse. This discrete choice experiment (DCE) assessed how ...
Pablo Balado-Simó,Marc Hernández-Santacana,Miguel Mansilla-Polo et al.
Pablo Balado-Simó et al.
Pediatric melanoma is a rare but clinically distinct malignancy, accounting for 1-4% of all melanoma cases. It encompasses unique subtypes-Spitzoid melanoma, melanoma arising in congenital melanocytic nevi, and conventional melanoma-each wi...
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study [0.03%]
伊兰迪银屑病（IL PSO）多中心回顾性研究中司库奇尤单抗治疗银屑病长达7年的有效性和安全性：真实世界证据
Luciano Ibba,Sara Di Giulio,Piergiorgio Malagoli et al.
Luciano Ibba et al.
Introduction: Secukinumab, approved in 2015 for the treatment of moderate-to-severe psoriasis, has demonstrated sustained efficacy and safety in pivotal randomized controlled trials. However, real-world data on its long-t...
New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review [0.03%]
银屑病或银屑病关节炎患者使用IL-23抑制剂治疗的新型结核感染和隐源性结核恶化：系统文献回顾
Gang Wang,Sang Woong Youn,Chia-Ling Chang et al.
Gang Wang et al.
Biologic agents, including the interleukin-23 (IL-23) inhibitors (IL-23is) guselkumab, risankizumab, and tildrakizumab, are effective therapies for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). However, the risk of latent ...
Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France [0.03%]
法国SNDS数据库驱动的III期可切除黑色素瘤流行病学与新辅助/辅助治疗模式的真实世界研究
Sandrine Monestier,Sebastien Branchoux,Louis Chillotti et al.
Sandrine Monestier et al.
Introduction: Before the advent of neoadjuvant immunotherapy (IO) in macroscopic disease, IO and targeted therapies were recommended as adjuvant therapies for the treatment of stage III resectable melanoma. However, real-...
Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA [0.03%]
美国成年和青少年 alopecia areata 患者 ritlecitinib 处方的患者特征及治疗情况
Justin Ko,Genevieve Gauthier,Samantha K Kurosky et al.
Justin Ko et al.
Introduction: In June 2023, the US Food and Drug Administration (FDA) approved ritlecitinib (50 mg once daily) for treatment of severe alopecia areata (AA) in patients ≥ 12 years. This study aimed to assess the character...